Literature DB >> 12871286

What is all that thrombin for?

K G Mann1, K Brummel, S Butenas.   

Abstract

The hemostatic process initiated by the exposure of tissue factor to blood is a threshold limited reaction which occurs in two distinct phases. During an initiation phase, small amounts of factor (F)Xa, FIXa and thrombin are generated. The latter activates the procofactors FV and FVIII to the activated cofactors which together with their companion serine proteases form the intrinsic FX activator (FVIIIa-FIXa) and prothrombinase (FVa-FXa) which generate the bulk of FXa and thrombin during a propagation phase. The clotting process (fibrin formation) occurs at the inception of the propagation phase when only 5-10 nM thrombin has been produced. Consequently, the vast majority (greater than 95%) of thrombin is produced after clotting during the propagation phase of thrombin generation. The blood of individuals with either hemophilia A or hemophilia B has no ability to generate the intrinsic FXase, and hence is unable to support the propagation phase of the reaction. Since clot based assays conclude before the propagation phase they are not sensitive to hemophilia A and B. The inception and magnitude of the propagation phase of thrombin generation is influenced by genetic polymorphisms associated with thrombotic and hemorrhagic disease, by the natural abundance of pro- and anticoagulants in healthy individuals and by pharmacologic interventions which influence thrombotic pathology. Therefore, it is our suspicion that the performance of the entire process of thrombin generation from initiation through propagation and termination phases of the reaction are relevant with respect to both hemorrhagic and thrombotic pathology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871286     DOI: 10.1046/j.1538-7836.2003.00298.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  110 in total

Review 1.  Promise of factor Xa inhibition in acute coronary syndromes.

Authors:  Leong Lee; Derek Chew
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

Review 2.  New anticoagulants in ischemic heart disease.

Authors:  Lawrence Rajan; David J Moliterno
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

Review 3.  Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.

Authors:  Qudsia Rashid; Poonam Singh; Mohammad Abid; Mohamad Aman Jairajpuri
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

Review 4.  The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.

Authors:  Elisabeth Perzborn; Susanne Roehrig; Alexander Straub; Dagmar Kubitza; Frank Misselwitz
Journal:  Nat Rev Drug Discov       Date:  2010-12-17       Impact factor: 84.694

5.  Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.

Authors:  Rami A Al-Horani; Akul Y Mehta; Umesh R Desai
Journal:  Eur J Med Chem       Date:  2012-06-23       Impact factor: 6.514

Review 6.  Recent pharmacological advances for treating venous thromboembolism: are we witnessing the demise of warfarin?

Authors:  Shankar Kumar; John Howell; Christopher Mattock
Journal:  J R Soc Med       Date:  2013-09-11       Impact factor: 5.344

7.  Protein S modulates the anticoagulant action of recombinant human activated protein C: a comparison between neonates and adults.

Authors:  Gerhard Cvirn; Martin Koestenberger; Bettina Leschnik; Christoph Male; Joerg Kutschera; Ulrika Ferstl; Wolfgang Muntean; Guenther Juergens; Siegfried Gallistl
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

8.  Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate.

Authors:  Johanna Zannoni; Natacha Mauz; Landry Seyve; Mathieu Meunier; Karin Pernet-Gallay; Julie Brault; Claire Jouzier; David Laurin; Mylène Pezet; Martine Pernollet; Jean-Yves Cahn; Fabrice Cognasse; Benoît Polack; Sophie Park
Journal:  Blood Adv       Date:  2019-06-25

Review 9.  Modeling thrombin generation: plasma composition based approach.

Authors:  Kathleen E Brummel-Ziedins; Stephen J Everse; Kenneth G Mann; Thomas Orfeo
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

10.  A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models.

Authors:  W P Sheffield; L J Eltringham-Smith; S Gataiance; V Bhakta
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.